Who are Olanzapine-samidorphan + exercise's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LYBALVI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olanzapine-samidorphan-exercise.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Olanzapine-samidorphan + exercise — Competitive Intelligence Brief

Olanzapine-samidorphan + exercise (Olanzapine-samidorphan + exercise) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic with opioid antagonist. Area: Psychiatry.

marketed Atypical antipsychotic with opioid antagonist Dopamine receptors, serotonin receptors (olanzapine); mu-opioid receptor (samidorphan) Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Olanzapine-samidorphan + exercise (Olanzapine-samidorphan + exercise) — New York State Psychiatric Institute. Olanzapine-samidorphan combines an atypical antipsychotic (olanzapine) with a mu-opioid receptor antagonist (samidorphan) to treat schizophrenia and bipolar disorder while mitigating weight gain, with exercise as a behavioral intervention.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Olanzapine-samidorphan + exercise TARGET	Olanzapine-samidorphan + exercise	New York State Psychiatric Institute	marketed	Atypical antipsychotic with opioid antagonist	Dopamine receptors, serotonin receptors (olanzapine); mu-opioid receptor (samidorphan)
LYBALVI	LYBALVI	Alkermes, Inc.	marketed	Atypical antipsychotic with opioid antagonist	D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic with opioid antagonist class)

Alkermes, Inc. · 1 drug in this class
New York State Psychiatric Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olanzapine-samidorphan + exercise — Competitive Intelligence Brief. https://druglandscape.com/ci/olanzapine-samidorphan-exercise. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab